基因降低人类脂蛋白(a)水平的表型特征
研究利用英国生物银行112338名参与者的个体数据、大规模全基因组关联研究汇总结果及LPA基因测序,评估基因降低Lp(a)水平与多种疾病风险的关联。结果显示Lp(a)每降低1个标准差,冠心病、外周血管病、卒中、心力衰竭和主动脉瓣狭窄风险均降低,且LPA功能获得性变异增加冠心病风险。
要点
- Lp(a)每降低1个标准差,冠心病风险OR为0.71(95%CI 0.69-0.73)。
- Lp(a)降低还与外周血管病(OR 0.69)、卒中(OR 0.87)、心衰(OR 0.83)、主动脉瓣狭窄(OR 0.63)风险降低相关。
- LPA基因功能获得性变异增加冠心病风险,功能缺失性变异降低冠心病风险。
核心结论
- 除冠心病外,基因降低Lp(a)水平与外周血管病、卒中、心力衰竭和主动脉瓣狭窄风险降低相关。
- 药理降低血浆Lp(a)可能影响一系列动脉粥样硬化相关疾病。
研究设计与样本
- 研究利用三个数据来源:英国生物银行112338名参与者的个体数据、大规模全基因组关联研究的汇总关联结果,以及冠心病病例与无冠心病对照的LPA基因测序结果。
- 研究目标为建立LPA基因变异的全表型影响,并估计基因改变的血浆Lp(a)与冠心病风险之间的剂量-反应曲线。
主要发现
- 基因降低Lp(a)水平1个标准差与冠心病风险降低29%相关(OR 0.71;95%CI 0.69-0.73)。
- 基因降低Lp(a)水平1个标准差与外周血管病风险降低31%相关(OR 0.69;95%CI 0.59-0.80)。
- 基因降低Lp(a)水平1个标准差与卒中风险降低13%相关(OR 0.87;95%CI 0.79-0.96)。
- 基因降低Lp(a)水平1个标准差与心力衰竭风险降低17%相关(OR 0.83;95%CI 0.73-0.94)。
- 基因降低Lp(a)水平1个标准差与主动脉瓣狭窄风险降低37%相关(OR 0.63;95%CI 0.47-0.83),并与另外31种疾病无关联,包括2型糖尿病和癌症。
关键数值与推荐
- 基因降低Lp(a)每1个标准差对应冠心病OR 0.71(95%CI 0.69-0.73)。
- 基因降低Lp(a)每1个标准差对应外周血管病OR 0.69(95%CI 0.59-0.80)。
- 基因降低Lp(a)每1个标准差对应卒中OR 0.87(95%CI 0.79-0.96)。
- 基因降低Lp(a)每1个标准差对应心力衰竭OR 0.83(95%CI 0.73-0.94)。
- 基因降低Lp(a)每1个标准差对应主动脉瓣狭窄OR 0.63(95%CI 0.47-0.83)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic analyses have suggested that the LPA gene and its associated plasma biomarker, lipoprotein(a) (Lp[a]), represent a causal risk factor for coronary heart disease (CHD). As such, lowering Lp(a) levels has emerged as a therapeutic strategy. Beyond target identification, human genetics may contribute to the development of new therapies by defining the full spectrum of beneficial and adverse consequences and by developing a dose-response curve of target perturbation. OBJECTIVES: The goal of this study was to establish the full phenotypic impact of LPA gene variation and to estimate a dose-response curve between genetically altered plasma Lp(a) and risk for CHD. METHODS: We leveraged genetic variants at the LPA gene from 3 data sources: individual-level data from 112,338 participants in the U.K. Biobank; summary association results from large-scale genome-wide association studies; and LPA gene sequencing results from case subjects with CHD and control subjects free of CHD. RESULTS: One SD genetically lowered Lp(a) level was associated with a 29% lower risk of CHD (odds ratio [OR]: 0.71; 95% confidence interval [CI]: 0.69 to 0.73), a 31% lower risk of peripheral vascular disease (OR: 0.69; 95% CI: 0.59 to 0.80), a 13% lower risk of stroke (OR: 0.87; 95% CI: 0.79 to 0.96), a 17% lower risk of heart failure (OR: 0.83; 95% CI: 0.73 to 0.94), and a 37% lower risk of aortic stenosis (OR: 0.63; 95% CI: 0.47 to 0.83). We observed no association with 31 other disorders, including type 2 diabetes and cancer. Variants that led to gain of LPA gene function increased the risk for CHD, whereas those that led to loss of gene function reduced the CHD risk. CONCLUSIONS: Beyond CHD, genetically lowered Lp(a) levels are associated with a lower risk of peripheral vascular disease, stroke, heart failure, and aortic stenosis. As such, pharmacological lowering of plasma Lp(a) may influence a range of atherosclerosis-related diseases.
引用
- Emdin CA, Khera AV, Natarajan P, et al. Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. J Am Coll Cardiol. 2016. PMID: 28007139. doi:10.1016/j.jacc.2016.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。